Sangamo BioSciences affirms full-year revenue, operating expense guidance

Sangamo BioSciences (SGMO) puts up a largely in line quarter (revenues come largely from collabs with Shire and Sigma-Aldrich).

R&D expense for the period was $8.7M, up from $7.6M in Q3 2012.

Full year guidance: Revenues of $20-24M and operating expenses of $46-50M. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs